Jadwal Sholat

Memuat jadwal sholatโ€ฆ

Kedokteran & Kesehatan editorial

Open AccessOA2024

Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

In a 'trial-like' ALS cohort, baseline serum NfL strongly predicted functional decline and survival, and improved the ENCALS clinical prediction model, yielding ~25% sample size savings. Other biomarkers (pNfH, p75ECD, miR-181ab) had limited added value.
M. Benatar; E. Macklin; A. Malaspina; Mary-Louise Rogers; E. Hornstein; V. Lombardi; Danielle Renfrey; Stephanie R. Shepheard; I. Magen; Yahel Cohen; V. Granit; J. Statland; J. Heckmann; R. Rademakers; Caroline A. McHutchison; L. Petrucelli; C. McMillan; J. Wuu; M. Benatar; V. Granit; J. Heckmann; L. Elman; J. Ravits; Jonathan S. Katz; J. Trivedi; A. Swenson; Ted M. Burns; J. Caress; Carlayne E. Jackson; S. Maiser; E. Pioro; Yuen T. Soยท medRxivยท 2024ยท DOI 10.1016/j.ebiom.2024.105323

The core problem

Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disease with variable progression rates, posing challenges for clinical trial design. Prognostic markers could improve trial efficiency by enabling enrichment, stratification, or covariate adjustment. However, among the many candidate clinical and biochemical markers, it is unclear which have real value and how they should be used. This study aimed to validate prognostic markers in a 'trial-like' ALS cohort and to quantify their potential impact on trial sample size.

Innovation

Patients with ALS were recruited through the multi-center Phenotype-Genotype-Biomarker study (clinicaltrials.gov: NCT02327845). A subset meeting common trial eligibility criteria was identified as 'trial-like'. Clinical phenotyping was performed by trained evaluators. Candidate prognostic markers included serum neurofilament light (NfL), serum phosphorylated neurofilament heavy (pNfH), urinary p75ECD, plasma microRNA-181, and an array of biochemical and clinical measures. Associations with functional progression were estimated using random-slopes mixed models of the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Associations with survival were assessed by log-rank test and Cox proportional hazards regression. Potential sample size savings from adjusting for biomarkers in a hypothetical trial were estimated.
Introduction
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disease with variable progression rates, posing challenges for clinical trial design. Prognostic markers could improve trial efficiency by enabling enrichment, stratification, or covariate adjustment. However, among the many candidate clinical and biochemical markers, it is unclear which have real value and how they should be used. This study aimed to validate prognostic markers in a 'trial-like' ALS cohort and to quantify their potential impact on trial sample size.

Why it matters

Among the multitude of biomarkers considered, only blood NfL added value to the ENCALS prediction model. These findings support incorporating NfL into analysis plans for all ongoing and future ALS trials. Defined thresholds of NfL might also be used in trial design, for enrichment or stratified randomisation, to improve trial efficiency. The study was funded by NIH (U01-NS107027, U54-NS092091) and ALSA (16-TACL-242).

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member contentโ€ฆ